文献速递眼底病与葡萄膜炎

口服酪氨酸激酶抑制剂治疗新生血管性年龄相关性黄斑变性:一项1期剂量递增研究

Oral Tyrosine Kinase Inhibitor for Neovascular Age-Related Macular Degeneration: A Phase 1 Dose-Escalation Study.
PubMed 文献 · JAMA Ophthalmol · 2017-01-01

这项1期、开放标签、非对照剂量递增研究在5家美国视网膜诊所纳入35例新生血管性年龄相关性黄斑变性患者,口服X-82 24周并联合按预设再治疗标准进行的玻璃体内抗VEGF治疗。最常见归因于X-82的不良事件为腹泻、恶心、疲劳和转氨酶升高,转氨酶升高均可逆;完成24周治疗的25例中除1例外视力维持或改善,15例无需抗VEGF注射。作者认为肝酶升高需肝功能检测识别不适合治疗者,进一步研究似乎合理,2期随机临床研究正在进行。

要点

  • 口服X-82 24周联合按预设标准抗VEGF治疗,完成治疗的25例中除1例外视力维持或改善(平均+3.8字母)。
  • 完成治疗的25例中15例(60%)无需抗VEGF注射(平均0.68次),平均中心子区视网膜厚度降低50 μm。
  • 最常见归因于X-82的不良事件为腹泻6例、恶心5例、疲劳5例、转氨酶升高4例。

核心结论

  • X-82可能与可逆性肝酶升高相关,因此需要肝功能检测以识别不适合治疗的患者。
  • 尽管17%的参与者因不良事件停用X-82,完成研究者抗VEGF注射率低于预期。
  • 进一步研究似乎合理,一项2期随机临床研究正在进行中。

研究设计与样本

  • 1期、开放标签、非对照、剂量递增研究,于2012年11月至2015年3月在美国5家视网膜诊所开展。
  • 纳入35例新生血管性年龄相关性黄斑变性患者,其中7例为未治疗者。
  • 参与者口服X-82 24周,剂量为50 mg隔日(n=3)、50 mg每日(n=8)、100 mg隔日(n=4)、100 mg每日(n=10)、200 mg每日(n=7)、300 mg每日(n=3),并联合按预设再治疗标准进行的玻璃体内抗VEGF治疗。
  • 每4周进行最佳矫正视力测量、眼底检查和频域光学相干断层扫描。

主要发现

  • 35例参与者平均年龄76.8岁,男性16例、女性19例,白人33例、非白人2例。
  • 完成24周X-82治疗的25例(71%)中,除1例外视力均维持或改善(均值[标准差]+3.8[9.6]字母)。
  • 完成治疗的25例中15例(60%)无需抗VEGF注射(均值0.68次)。
  • 平均[标准差]中心子区视网膜厚度降低50[97] μm,其中8例(均接受至少100 mg每日)在未注射抗VEGF情况下显示持续降低。
  • 最常见归因于X-82的不良事件为腹泻(n=6)、恶心(n=5)、疲劳(n=5)和转氨酶升高(n=4);转氨酶升高未发现剂量关系,停用X-82后均恢复正常,除1例外均无症状。

关键数值与推荐

  • 主要结局为不良事件;其他结局包括视力、中心子区视网膜厚度和抗VEGF注射次数。
  • 完成24周X-82治疗的25例中,除1例外视力维持或改善,平均[标准差]+3.8[9.6]字母。
  • 完成治疗的25例中15例(60%)无需抗VEGF注射,平均0.68次。
  • 平均[标准差]中心子区视网膜厚度降低50[97] μm,8例(均接受至少100 mg每日)在未注射抗VEGF情况下显示持续降低。

临床怎么用

  • 作者认为,X-82可能与可逆性肝酶升高相关,因此需要肝功能检测以识别不适合治疗的患者。
  • 作者指出,尽管17%的参与者因不良事件停用X-82,完成研究者抗VEGF注射率低于预期。
  • 作者认为进一步研究似乎合理,一项2期随机临床研究正在进行中。

局限性

  • 原文为1期、开放标签、非对照、剂量递增研究。
  • 原文样本量为35例参与者。
  • 10例撤回知情同意或提前终止,其中6例因归因于X-82的不良事件。
  • 作者指出进一步研究似乎合理,一项2期随机临床研究正在进行中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: An oral treatment for neovascular age-related macular degeneration would be less burdensome than repeated intravitreous injections. X-82 is an oral tyrosine kinase inhibitor active against vascular endothelial growth factor (VEGF) and platelet-derived growth factor. OBJECTIVE: To undertake safety testing of oral X-82 administered for the treatment of neovascular AMD. DESIGN, SETTING, AND PARTICIPANTS: Phase 1, open-label, uncontrolled, dose-escalation study at 5 US retinal clinics between November 2012 and March 2015 (Retina-Vitreous Associates Medical Group, Beverly Hills, California; Blanton Eye Institute, Houston Methodist Hospital, Retina Consultants of Houston, Houston, Texas; New England Retina Associates, Guilford, Connecticut; Elman Retina Group, Baltimore, Maryland; and Retina Research Institute of Texas, Abilene). Thirty-five participants with neovascular age-related macular degeneration, 7 of whom were treatment naive. INTERVENTIONS: Participants received oral X-82 for 24 weeks at 50 mg alternate days (n = 3), 50 mg daily (n = 8), 100 mg alternate days (n = 4), 100 mg daily (n = 10), 200 mg daily (n = 7), and 300 mg daily (n = 3), with intravitreous anti-VEGF therapy using predefined retreatment criteria. Every 4 weeks, participants underwent best-corrected visual acuity measurement, fundus examination, and spectral-domain optical coherence tomography. MAIN OUTCOMES AND MEASURES: The main outcome was adverse events. Other outcomes included visual acuity, central subfield retinal thickness, and number of anti-VEGF injections. RESULTS: Of the 35 participants, the mean age was 76.8 years, 16 were men and 19 were women, and 33 were white and 2 were nonwhite. Of 25 participants (71%) who completed the 24 weeks of X-82 treatment, all except 1 maintained or improved their visual acuity (mean [SD], +3.8 [9.6] letters). Fifteen participants (60%) required no anti-VEGF injections (mean, 0.68). Mean [SD] central subfield thickness reduced by -50 [97] μm, with 8 participants (all receiving at least 100 mg daily) demonstrating sustained reductions despite no anti-VEGF injections. The most common adverse events attributed to X-82 were diarrhea (n = 6), nausea (n = 5), fatigue (n = 5), and transaminase elevation (n = 4). A dose relationship to the transaminase elevations was not identified; all normalized when X-82 was discontinued. All but 1 were asymptomatic. Ten participants withdrew consent or discontinued prematurely, 6 owing to adverse events attributed to X-82 including leg cramps (n = 2), elevated alanine aminotransferase (n = 2), diarrhea (n = 1), and nausea/anorexia (n = 1). CONCLUSIONS AND RELEVANCE: X-82 can be associated with reversible, elevated liver enzymes; hence, liver function testing is needed to identify those unsuited to treatment. Although 17% of participants discontinued X-82 owing to AEs, those who completed the study had lower than expected anti-VEGF injection rates. Further studies appear justified, with a phase 2 randomized clinical study under way.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Jackson TL, Boyer D, Brown DM, et al. Oral Tyrosine Kinase Inhibitor for Neovascular Age-Related Macular Degeneration: A Phase 1 Dose-Escalation Study. JAMA Ophthalmol. 2017. PMID: 28570723. doi:10.1001/jamaophthalmol.2017.1571

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。